HER2/neu is a protein that sits on the surface of cells and, when present in excess, acts as a powerful accelerant for tumor growth. Roughly 15 to 30 percent of breast cancers and a similar fraction of gastric cancers overexpress or amplify the gene that encodes it, making HER2 status one of the most consequential pieces of information in a cancer diagnosis.1PubMed Central. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications What transformed HER2 from a grim prognostic marker into a treatment success story is a suite of drugs designed to exploit the very receptor that fuels the cancer, though the biology turns out to be more layered than the textbook version suggests.
What HER2 Actually Does in Healthy and Cancerous Cells
HER2 belongs to a family of four related receptors (EGFR/HER1, HER2, HER3, and HER4) embedded in the outer membrane of many cell types. These receptors normally help regulate growth, division, and repair. What makes HER2 unusual is that it does not need its own growth-factor signal to become active. Its structure is permanently in an “open” configuration, ready to pair up with another receptor. When it finds a partner, the pair triggers internal signaling cascades that tell the cell to grow and survive.
In healthy tissue, HER2 pairing is tightly controlled. Computational modeling has shown that normal-cell HER2 structures do not form stable homodimers at all, whereas cancer-cell HER2 structures readily produce numerous stable pairings with far stronger interaction energies.2Exploration of Medicine. Structural biology of HER2/ERBB2 dimerization: mechanistic insights and differential roles in healthy versus cancerous cells That stability difference helps explain why extra copies of HER2 on a cancer cell’s surface create a self-reinforcing growth signal that a normal cell never generates.
One of HER2’s most important partnerships is with HER3. Cryo-electron microscopy has revealed that the active HER2/HER3 pair assembles in a distinctive heart-shaped dimer, but with an unexpected twist: the HER3 “dimerization arm,” normally considered essential for receptor pairing, is not resolved in the structure. Only HER2’s arm makes the key contacts, interacting with HER3 through a handful of specific backbone and side-chain connections.3bioRxiv. Structures of the active HER2/HER3 receptor complex reveal dynamics at the dimerization interface induced by binding of a single ligand This means HER2 does not need to undergo major shape changes to engage its partners; it is essentially always ready to go, which makes overexpression especially dangerous.
Once paired, HER2/HER3 dimers predominantly activate the PI3K/AKT signaling pathway, a major pro-survival route in cancer cells. However, the degree to which the related MAPK pathway is also activated varies by cancer type and by which other receptors are present on the cell surface.4PubMed Central. HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B This variability matters because two HER2-positive tumors can behave quite differently depending on their downstream wiring.
HER2 in Breast Cancer and Beyond
Breast cancer is where HER2 was first recognized as clinically important, and it remains the cancer type most closely associated with the receptor. Early studies established that HER2 amplification correlated with more aggressive disease: tumors tended to be larger, more likely to have spread to lymph nodes, and more often lacking estrogen and progesterone receptors.5Cancer Research. HER-2/neu Amplification Predicts Poor Survival in Node-positive Breast Cancer Before targeted therapies existed, HER2-positive status was essentially a marker of poor prognosis.
HER2 overexpression is not limited to the breast, though. Gastric and gastroesophageal junction cancers show amplification rates of roughly 10 to 30 percent.1PubMed Central. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications Colorectal cancer has lower rates. In a large genomic analysis of metastatic colorectal cancers, about 4.8 percent carried ERBB2 (the gene name for HER2) amplification or short-variant alterations.6PubMed Central. Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3 An important complication in colorectal tumors is that HER2 status can differ between the primary tumor and its metastases. One study found that only about 5 percent of patients showed the same HER2 amplification in both their primary and metastatic sites, while some patients were positive in one location but negative in the other.7PubMed Central. Comparison of HER2 expression between primary colorectal cancer and their corresponding metastases This discordance raises real questions about whether a single biopsy can reliably guide treatment decisions for metastatic disease.
In colorectal cancer, the location of HER2 on the cell also matters. Strong staining on the cell membrane, as opposed to inside the cell’s cytoplasm, is strongly associated with actual gene amplification. Cytoplasmic HER2 staining, which is quite common in colorectal primaries, appears to be more of a marker of how well the tumor is differentiated than a driver of growth.8PubMed. HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors
How HER2 Status Is Tested
Determining whether a tumor is HER2-positive involves a two-step process in most clinical settings. The initial screen is immunohistochemistry (IHC), which stains a tissue sample to show how much HER2 protein is present on cell surfaces. Scores range from 0 (no staining) through 1+ (faint), 2+ (moderate), to 3+ (strong, uniform staining). A score of 3+ is considered positive. A score of 0 or 1+ is negative. The ambiguous middle ground, IHC 2+, gets sent for a second test.
That second test is fluorescence in situ hybridization (FISH), which counts actual copies of the HER2 gene in each cell. FISH is considered the more definitive measure. A study comparing the methods found that strong FISH amplification correlated tightly with IHC 3+ status, while equivocal and other FISH groups were more often associated with IHC 0 or 1+.9PubMed Central. HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH) The guidelines for interpreting these results have been refined over time. A comparison of the 2013 and 2018 ASCO/CAP guidelines found that the newer criteria improved the accurate sorting of equivocal cases, with concordance between FISH and genomic assays reaching nearly 100 percent under the updated rules.10PubMed Central. HER2 testing in breast cancers: comparison of assays and interpretation using ASCO/CAP 2013 and 2018 guidelines
A newer frontier in testing involves liquid biopsies, which analyze circulating tumor DNA from a standard blood draw rather than requiring a tissue sample. In breast cancer patients, one study found that circulating HER2 copy numbers agreed with tissue-based HER2 status about 87 percent of the time, with particularly high accuracy when tissue showed strong amplification.11PubMed Central. Longitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancer In gastric cancer, a digital droplet PCR-based blood test has been validated against standard tissue methods and used to track changes in HER2 status during treatment, with shifts in circulating HER2 copy numbers reflecting whether therapy was working or resistance was emerging.12PubMed Central. Liquid biopsy based HER2 amplification status in gastric cancer patients indicates clinical response The appeal of blood-based testing is obvious: it avoids repeated invasive biopsies and can be done at regular intervals to monitor the disease in real time. That said, reviews of the field note that while many studies have been published, full analytical and clinical validation of liquid biopsy approaches for HER2 is still lacking.13Cancer Treatment Reviews. HER2/neu: Its Role in Cancer, Diagnosis, and Treatment
Targeted Treatments That Changed HER2-Positive Cancer
Trastuzumab, the first HER2-targeting antibody, works by binding to the extracellular portion of the HER2 receptor. This blocks receptor pairing and also flags the cancer cell for destruction by the immune system. Natural killer cells exposed to trastuzumab-coated cancer cells mount a strong cytotoxic attack, while monocytes shift toward engulfing the tumor cells through phagocytosis.14PubMed Central. Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients The drug transformed HER2-positive breast cancer from one of the worst subtypes to one with genuinely favorable outcomes when caught early.
Pertuzumab, a second antibody, binds a different spot on HER2, specifically blocking its ability to pair with HER3. When combined with trastuzumab, the two antibodies act synergistically, meaning the combined effect is far greater than either alone. Lab studies found combination index values below 0.1, indicating very strong synergism against HER2-positive breast cancer cells.15Cancer Research. The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells This dual-antibody strategy, often combined with chemotherapy, became a standard regimen for HER2-positive disease. Strategies to prevent activation of the HER3 partner through various means, including blocking its dimerization with HER2 or targeting HER3 directly, represent an active area of drug development.16PubMed Central. Molecular pathways: HER3 targeted therapy
Antibody-Drug Conjugates and the Bystander Effect
A newer class of treatments, antibody-drug conjugates (ADCs), takes the targeting ability of an anti-HER2 antibody and attaches a potent chemotherapy payload directly to it. The antibody delivers the drug specifically to cells displaying HER2, theoretically sparing normal tissue. Two ADCs in clinical use highlight how design details dramatically affect performance.
Trastuzumab emtansine (T-DM1) uses a non-cleavable linker to attach a microtubule-inhibiting drug. Trastuzumab deruxtecan (T-DXd) uses a cleavable linker that releases a membrane-permeable topoisomerase I inhibitor once inside the cancer cell’s lysosome. Both are effective at killing HER2-positive cells. The critical difference emerges in mixed tumors. In co-culture experiments with HER2-positive and HER2-negative cells, T-DXd caused significant death of the HER2-negative bystander cells, while T-DM1 did not.17Molecular Cancer Therapeutics. Comparison of the bystander effects and killing capabilities of the HER2-targeting antibody drug conjugates T-DM1 and T-DXd This “bystander effect” means T-DXd’s released drug can diffuse into neighboring cells that lack the target, killing them too.
This property led to a conceptual shift in how oncologists think about HER2 targeting. Because T-DXd can kill nearby HER2-negative cells, tumors that express only low levels of HER2 became treatable. This observation drove the recognition of “HER2-low” as a clinically meaningful category, defined as IHC 1+ or IHC 2+ with negative in situ hybridization.18The Lancet Oncology. HER2-low breast cancer and its relation to pathological complete response and survival Tumors previously dismissed as HER2-negative could now be candidates for targeted therapy, expanding the population that might benefit.19PubMed Central. Antibody-Drug Conjugates in Breast Cancer: Spotlight on HER2
When the Cancer Spreads to the Brain
Brain metastases are a feared complication of HER2-positive breast cancer. Large antibodies like trastuzumab and pertuzumab cannot easily cross the blood-brain barrier, which leaves a gap in treatment. Small-molecule tyrosine kinase inhibitors can penetrate into the brain, but not all are equally effective at doing so.
Pharmacokinetic modeling has compared the three HER2 kinase inhibitors used clinically: tucatinib, lapatinib, and neratinib. After a standard dosing cycle, tucatinib and lapatinib achieved similar levels of unbound drug in brain tissue, while neratinib’s brain exposure was roughly 20-fold lower. However, the three drugs differ in potency. Tucatinib and neratinib are equally potent at inhibiting HER2 at similar concentrations, while lapatinib is more than tenfold less potent. When both drug levels and potency are combined into a “target engagement ratio,” tucatinib came out substantially ahead: a ratio of about 2.1 in intact brain tissue, compared with less than 0.2 for both lapatinib and neratinib. Even in brain metastases where the barrier is disrupted, tucatinib’s ratio climbed to around 5.4, while lapatinib and neratinib remained below 1.0.20Clinical Cancer Research. Mechanistic Modeling of Central Nervous System Pharmacokinetics and Target Engagement of HER2 Tyrosine Kinase Inhibitors to Inform Treatment of Breast Cancer Brain Metastases These numbers suggest tucatinib is the most promising of the three for reaching and effectively inhibiting HER2 in the brain.
How Tumors Become Resistant to HER2-Targeted Therapy
Not every HER2-positive tumor responds to targeted drugs, and many that initially respond eventually stop. Several resistance mechanisms have been identified, but one of the more striking is the production of a truncated version of the receptor called p95HER2. Enzymes on the cell surface can cleave the extracellular portion of HER2, leaving behind a 95 kilodalton fragment that still signals aggressively but lacks the binding site that trastuzumab needs to attach. p95HER2 can form its own dimers, activating downstream growth pathways while the drug sits uselessly in the bloodstream.21Frontiers in Oncology. Resistance mechanisms and prospects of trastuzumab
Another source of treatment failure is intratumoral heterogeneity, where different parts of the same tumor express different levels of HER2. This is not rare: one study found HER2 heterogeneity in nearly a quarter of biopsies, and its presence was significantly associated with lower rates of complete pathological response to neoadjuvant therapy.22PubMed Central. HER2 intratumoral heterogeneity predicts response to neoadjuvant therapy in HER2-positive breast cancer: impact and interplay with HER3 expression Patients whose tumors show this kind of genetic patchwork tend to have shorter disease-free survival.23Modern Pathology. Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance The heterogeneity problem interacts with resistance in a vicious cycle: HER2-negative clones within a mixed tumor are selected for survival when treatment kills off the HER2-positive ones.24PubMed Central. HER2 Intratumoral Heterogeneity in Breast Cancer, an Evolving Concept This is exactly the scenario where T-DXd’s bystander effect could matter most, by reaching cells that do not display the target.
Heart Risks from HER2-Targeted Therapy
HER2 is not exclusive to tumor cells. It is also expressed in heart muscle, where it plays a role in cellular repair and survival. Blocking it with trastuzumab can cause cardiac side effects, most commonly a decline in the heart’s pumping efficiency. A meta-analysis of ten randomized controlled trials found that about 7.5 percent of patients receiving trastuzumab experienced a measurable drop in left ventricular ejection fraction, and roughly 2 percent developed congestive heart failure.25PubMed Central. Mechanisms of trastuzumab induced cardiotoxicity – is exercise a potential treatment? In patients treated with trastuzumab but not anthracyclines (a class of chemotherapy known to compound heart damage), the rate of hospitalization or emergency visits for heart failure or cardiovascular death was about 5 percent. The cardiotoxicity from trastuzumab differs from that caused by anthracyclines in an important way: it is usually reversible if the drug is stopped, whereas anthracycline damage tends to be permanent. Patients receiving trastuzumab undergo regular cardiac monitoring, typically with echocardiograms every few months.
Equity in Access to HER2-Targeted Treatments
The drugs that have made HER2-positive cancer so much more treatable are expensive, and access to them is uneven worldwide. In many low- and middle-income countries, patients with HER2-positive breast cancer receive only standard chemotherapy because targeted agents are unavailable or unaffordable.26PubMed Central. Access to high-cost drugs for advanced breast cancer in Latin America, particularly trastuzumab A recent global expert review found that disparities in access to advanced breast cancer care are widening, with delays in diagnostic services and infrastructure barriers compounding the problem of drug cost.27PubMed Central. Improving equitable access to comprehensive care for people with advanced breast cancer
Disparities exist within high-income countries as well. In the United States, a study of Medicare beneficiaries from 2010 through 2020 found that Black and Hispanic patients were less likely to receive HER2-targeted therapy compared with White patients. The gap was statistically significant for much of the study period, though by 2018–2019 the racial and ethnic differences were no longer significant, suggesting some improvement over time.28PubMed Central. Racial and Ethnic Disparities in Receipt of ERBB2-Targeted Therapy for Breast Cancer, 2010-2020 Still, the fact that it took nearly a decade after trastuzumab became standard of care for access to equalize even within a single national insurance program underlines how slowly equity gains happen in practice.
Experimental Approaches on the Horizon
Beyond antibodies, ADCs, and small-molecule inhibitors, researchers are exploring immune-cell-based therapies that use HER2 as a homing signal. One approach involves engineering T cells with a built-in activation signal and then arming them with bispecific antibodies that bridge the T cell to HER2-positive tumor cells. In preclinical testing, these armed T cells killed multiple tumor lines significantly better than control T cells and released inflammatory signaling molecules upon encountering tumor cells, even at ratios of just one or two T cells per cancer cell.29Frontiers in Immunology. Bispecific Antibody Armed Metabolically Enhanced Headless CAR T Cells The advantage of bispecific antibody-armed T cells over traditional CAR-T therapy is flexibility: the antibody can be swapped or combined, so if a tumor loses HER2 expression, the same T-cell platform could potentially be redirected to a different target.
Whether these cellular therapies translate from the lab into practical treatments for solid tumors remains an open question. Solid tumors present hurdles that blood cancers do not, including a hostile microenvironment that suppresses immune cells and physical barriers to T-cell infiltration. Still, the pace of innovation in HER2-directed therapy over the past two decades has been faster than in almost any other area of oncology, and the receptor’s accessibility on the cell surface continues to make it a prime target for whatever the next generation of treatment turns out to be.